key: cord-0872432-hglphure authors: Araiza-Garaygordobil, D; Montalto, C; Martinez-Amezcua, P; Cabello-Lopez, A; Gopar-Nieto, R; Alabrese, R; Almaghraby, A; Catoya-Villa, S; Chacon-Diaz, M; Kaufmann, C C; Corbi-Pascual, M; Deharo, P; El-Tahlawi, M; Elgohari-Abdelwahab, A; Guerra, F; Jarakovic, M; Martinez-Gomez, E; Moderato, L; Montero, S; Morejon-Barragan, P; Omar, A M; Jorge-Pérez, P; Przybyło, P; Selim, E; Sinan, U Y; Stratinaki, M; Tica, O; Trêpa, M; Uribarri, A; Uzokov, J; Wilk, K; Czerwińska-Jelonkiewicz, K; Sionis, A; Gierlotka, M; Leonardi, S; Krychtiuk, K A; Tavazzi, G title: Impact of the COVID-19 pandemic on hospitalizations for acute coronary syndromes: a multinational study date: 2021-01-24 journal: QJM DOI: 10.1093/qjmed/hcab013 sha: f0ec2e335df82e1d37bd8c82b48d39af8e142208 doc_id: 872432 cord_uid: hglphure Background: COVID-19 has challenged the health system organization requiring a fast reorganization of diagnostic/therapeutic pathways for patients affected by time-dependent diseases such as acute coronary syndromes (ACS). Aim: To describe ACS hospitalizations, management, and complication rate before and after the COVID-19 pandemic was declared. Design: Ecological retrospective study. Methods: We analyzed aggregated epidemiological data of all patients > 18 years old admitted for ACS in twenty-nine hub cardiac centers from 17 Countries across 4 continents, from December 1st, 2019 to April 15th, 2020. Data from December 2018 to April 2019 were used as historical period. Results: A significant overall trend for reduction in the weekly number of ACS hospitalizations was observed (20.2%; 95% confidence interval CI [1.6, 35.4] P = 0.04). The incidence rate reached a 54% reduction during the second week of April (incidence rate ratio: 0.46, 95% CI [0.36, 0.58]) and was also significant when compared to the same months in 2019 (March and April, respectively IRR: 0.56, 95%CI [0.48, 0.67]; IRR: 0.43, 95%CI [0.32, 0.58] p < 0.001). A significant increase in door-to-balloon, door-to-needle, and total ischemic time (p <0.04 for all) in STEMI patents were reported during pandemic period. Finally, the proportion of patients with mechanical complications was higher (1.98% vs. 0.98%; P = 0.006) whereas GRACE risk score was not different. Conclusions: Our results confirm that COVID-19 pandemic was associated with a significant decrease in ACS hospitalizations rate, an increase in total ischemic time and a higher rate of mechanical complications on a international scale. Since the first reported cases from the Chinese city of Wuhan in December of 2019, Coronavirus Disease 2019 (COVID-19) has grown to a pandemic infecting more than 87 million individuals and causing more than 1.8 million deaths as of the beginning of January 2021. [1] [2] Healthcare systems have been challenged due to the COVID-19 pandemic, which has led to a complete reorganization of all the acute care diagnostic and therapeutic pathways. The combination of overwhelmed health care systems and the strict social containment measures may have had an impact on the illness threshold at which the patients with other diseases than COVID-19 seek for medical care. Previous reports from Hong Kong observed that the time of first medical contact of patients with acute coronary syndrome (ACS) increased since late January 2020, compared to a 12-month period preceding the pandemic onset.1 Additionally, the total number of hospitalizations, diagnostic and therapeutic procedures performed for ACS decreased after the COVID-19 outbreak in several country reports. [3] [4] [5] [6] [7] [8] As cardiovascular disease represents the leading cause of death worldwide, 9 identifying how the care of patients with ACS could be affected by the COVID-19 pandemic is of paramount importance. This study aims to describe the clinical characteristics, temporal trends, treatment, complications and outcomes in ACS hospitalizations before and after the onset of the COVID-19 pandemic at a multinational level. The study was conducted through the network of Young Community from the Association for Acute Cardiovascular Care (ACVC) of the European Society of Cardiology. All participant centers were regional hub hospitals for the treatment of ACS with either primary percutaneous coronary intervention (pPCI) or fibrinolysis before and after the onset of the COVID-19 pandemic. All adult patients (18 years old) admitted for ACS [including ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI) and unstable angina] were included in this study. Data were retrospectively retrieved from patients' medical history records and hospital discharge files. The protocol was approved by the ethical committee from the principal investigator's institution and complies with the principles of the Declaration of Helsinki. Due to the ecological nature of the data, informed consent was waived. Data of patients consecutively admitted for ACS from 1 December 2019 to 15 April 2020 were considered for the study. Additionally, the period from 1 December 2018 to 30 April 2019 was considered as historical comparison period. Data were aggregated and expressed in monthly rates for December 2019-February 2020 and in weekly rates for the period after 1 March 2020. For the historical comparison, monthly aggregation was used. Clinical characteristics, temporal trends in ACS hospitalization rates, chosen treatment strategy, time to treatment, complications and in-hospital outcomes were collected from all patients fulfilling the inclusion criteria during the study period in each center and aggregated in a central database. We defined the pandemic period after 11 March 2020, according to the World Health Organization (WHO) declaration of the COVID-19 pandemic, 3 and compared trends with the 14 preceding weeks (1 December 2019-10 March 2020). To account for potential seasonal trends, we compared monthly ACS hospitalization rates in the observed timeframe with historic controls from the previous year (i.e. March 2020 vs. March 2019). Finally, to account for potential geographical and temporal dispersion of the COVID-19 outbreak, the date of the declaration of national emergency for each country was considered in a sensitivity analysis to define the onset of the pandemic period. The primary outcome of the study was the comparison between ACS weekly admission rates in pre-pandemic and pandemic periods. Additionally, we compared ACS monthly rates of prepandemic and pandemic periods with the historical comparison. Secondary outcomes included the proportion of patients treated by percutaneous coronary intervention (PCI), total ischemic time, as well as door-to-balloon/door-to-needle times (for patients with STEMI) and GRACE score. Rate of mechanical complications was also analyzed. Primary PCI was defined as a percutaneous coronary intervention procedure performed during the first 12 h since symptoms onset. Ischemic time was defined as the total time, in minutes, between symptom onset and the guidewire crossing or lytic IV injection. Door to balloon and door to needle were defined as time from hospital presentation to guidewire crossing or lytic IV injection, respectively. 10 Mechanical complications were recorded as a composite frequency that included acute severe mitral regurgitation, ventricular septal defect and cardiac rupture/tamponade. The weekly average rate was calculated by dividing the ACS events with the week considered (i.e. 14 weeks from 1 December 2019 to 11 March 2020). The relative differences in weekly rates between the pandemic and pre-pandemic periods were estimated using generalized linear regression models with a Poisson distribution, and we used robust estimation of variance and accounted for clustering of the data by center. A joinpoint regression analysis was performed to assess fluctuating trends over time in the weekly ACS rates after the WHO pandemic declaration. This analysis aimed to identify both an overall percentage change during the post-pandemic period and any timepoint in which the trend in ACS rates significantly changed (from 1 week to another). For both analyses, an overall percentage change during those periods were reported. We compared the mean GRACE scores, time to treatment and total ischemic time by type of ACS. Door-to-balloon, doorto-needle times (for STEMI) and treatment used (by type of ACS) were compared between pre-pandemic and pandemic periods using paired t-tests. To compare the proportion of patients who underwent PCI and developed mechanical complications, we performed chi-squared tests. A total of 29 centers from 17 countries were enrolled in the study. A complete list of participant centers is included in Supplementary Appendix A. Across the three study periods, a total of 16 117 patients with ACS were admitted to the participant centers (pre-pandemic period ¼ 5923; pandemic period ¼ 1444; historical control period ¼ 8750). Table 1 shows the absolute admissions through each study period according to individual diagnosis (ST elevation ACS and/non-ST elevation ACS). When compared to the pre-pandemic period, a significant overall trend for reduction of 20.2% in the weekly number of ACS hospitalizations was observed during the pandemic period (95% confidence interval CI [1.6, 35.4], P ¼ 0.04) (Figure 1 ). The maximal reduction in the incidence rate was 54% during the second week of April compared with the pre-pandemic period To account for the difference in ACS hospitalization rates between WHO pandemic declaration and the date of national emergency declaration of each of the participating countries, a sensitivity analysis was conducted, and the results are summarized in Table 2 . This alternative model confirmed the reductions in ACS weekly admissions, up to a 63% decrease during the fifth week after the pandemic onset as defined at a countrylevel (IRR for the fifth week: 0.37, 95% CI [0.28-0.49], P < 0.001). A table including the date of national emergency declaration for each country is included in Supplementary Appendix C. A significant reduction of patients undergoing pPCI was observed (81.8% pre-pandemic vs. 76.2% pandemic, difference: -5.6%, P ¼ 0.041), with no significant difference in the proportion of patients undergoing systemic fibrinolysis (11.8% prepandemic vs. 14.7% pandemic, difference: þ2.8%, P ¼ 0.56). A significant delay was reported in total ischemic time (relative difference þ22.7 min; P ¼ 0.02), door-to-balloon (relative difference þ11.2; P ¼ 0.04) and door-to-needle times (relative difference þ48.3 min; P < 0.004). No significant differences were noted in the rate of NSTEMI patients undergoing either PCI (70.3% prepandemic vs. 73.6% pandemic, difference: þ3.0%, P ¼ 0.29) or CABG (8.3% pre-pandemic vs. 12 The pandemic period was defined for each country from the date of the declaration of emergency. Our study reports a significant decrease in hospitalizations for ACS after the WHO COVID-19 pandemic declaration in several countries worldwide. Furthermore, among patients with STEMI, a lower rate of pPCI with significant increase in patient and system-related delays and a higher rate of mechanical complications were observed. A disruption in the diagnostic/therapeutic pathway of acute diseases, including ACS, has been reported during previous infectious disease outbreaks. 11 Furthermore, previous studies during SARS-CoV-1 outbreak reported changes in ACS hospitalization rates with substantial decreases in cardiac catheterizations, 12 which were likely explained by restrictions in the use of health care services affecting the access for some potentially seriously ill patients. It was therefore expected that COVID-19 pandemic would result in a significant reduction in emergency department and hospital admissions with related procedures. According to data from a STEMI registry and reports from Europe, a steep decline in the admissions after the COVID-19 lockdown has been observed, [5] [6] [7] [8] which is consistent with our results on a wider perspective. De Filippo et al. 5 reported the results of a retrospective multicentric analysis of consecutive patients admitted for ACS at 15 hospitals from Italy after national COVID-19 outbreak, demonstrating a reduction of 26% in the number of admissions when compared with the previous months, and a reduction of 30% when compared the previous year. Similarly, in another report comprising 10% of the Italian population, a significant decline in the rates of PCI both for NSTEMI and STEMI was observed. 6 Likewise, a reduction of 38% in STEMI prevalence has been also observed in the USA after the national COVID-19 outbreak. 4 An increased complication rate was also observed in a nationwide survey, although limited to a 1-week enrollment. 7 The reasons behind the decline of procedure rates and prolonged times to treatment may be several. Dyspnea and chest pain are common overlapping symptoms of both, overt ischemia and COVID-19, which makes the differential diagnosis more challenging 13, 14 and potentially leads to prolonged reperfusion times. Additionally, besides the reluctance of patients seeking care, the infection and prevention control measures may have played a role in prolonging the patient's clinical evaluation and procedure organization. 15 Outcomes of patients presenting with ACS have progressively improved over the last decades also due to the institution of dedicated networks. 16 Delayed reperfusion time may be the explanation of a higher mechanical complication rate. For the same reason, the incidence of chronic heart failure with adverse remodeling might be expected to increase in the near future among patients who survive the acute setting. Furthermore, a concerning increase is out-of-hospital cardiac arrest, as a higher number of cases has also been observed during the COVID-19 pandemic. 17 Finally, it is interesting to note that the reduction of ACS hospitalization was observed in the vast majority of countries involved in the present study, including those initially less affected by the COVID-19 pandemic. These results highlight the need for health care awareness and strategies for emergency network reorganization to ensure rapid, easy and safe access to patients with time-dependent illness. Our study has limitations. First, data from the participant centers may not be representative for their country. Thus, our findings may not reflect a true decrease in the looking for medical attention in patients with ACS as those patients may have sought attention elsewhere. Additionally, due to the ecologic nature of the present study, we did not stratify patients on clinical phenotype, and we were not able to provide clinical characteristics among patients in different study periods. Our results confirm that COVID-19 pandemic onset was associated with a significant decrease in ACS hospitalizations rate, an increase in total ischemic time and time to treatment in STEMI and a higher rate of mechanical complications. Actions to improve the patients' awareness and quality of care of patients with ACS during the COVID-19 pandemic are advocated. Supplementary material is available at QJMED online. World Health Organization Regional Office for Europe. WHO Announces COVID-19 Outbreak Pandemic Impact of Coronavirus Disease 2019 (COVID-19) outbreak on ST-segment-elevation myocardial infarction care in Hong Kong Reduction in ST-segment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemic Reduced rate of hospital admissions for ACS during Covid-19 outbreak in Northern Italy Population trends in rates of percutaneous coronary revascularization for acute coronary syndromes associated with the COVID-19 outbreak Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era Decline of acute coronary syndrome admissions in Austria since the outbreak of COVID-19: the pandemic response causes cardiac collateral damage Heart Disease and Stroke Statistics-2020 Update: a Report from the American Heart Association ESC Guidelines for the management of acute myocardial infarction in patients presenting with STsegment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with STsegment elevation of the European Society of Cardiology (ESC) Effect of widespread restrictions on the use of hospital services during an outbreak of severe acute respiratory syndrome Utilization of Ontario's Health System during the 2003 SARS outbreak Collateral damage: medical care avoidance behavior among patients with myocardial infarction during the COVID-19 pandemic Misdiagnosis in the COVID-19 Era: when zebras are everywhere, don't forget the horses The untold toll -the pandemic's effects on patients without Covid-19 Networks for improving care in patients with acute coronary syndrome: a framework Lombardia CARe Researchers. Out-of-hospital cardiac arrest during the Covid-19 outbreak in Italy We are infinitely grateful to Dr Alexandra Arias for her help in the development of this study. No funding was received for the development of this study.Conflict of interest. None declared.